Investment
Features
FeesSafety
Academy
More
Pluang+

Compare GraniteShares 2x Long COIN Daily ETF (CONL) vs Mesoblast Limited (MESO) Price & Performance

GraniteShares 2x Long COIN Daily ETFTrade
Mesoblast LimitedTrade

Price performance (Past 24H)

Key statistics

GraniteShares 2x Long COIN Daily ETF vs Mesoblast Limited — how do they compare? GraniteShares 2x Long COIN Daily ETF trades at $4.18, while Mesoblast Limited trades at $16.68 (market cap $2.16B). The key difference: Mesoblast Limited is trading nearer its 52-week high, GraniteShares 2x Long COIN Daily ETF nearer its low. Which is the better fit depends on your goals.

CONLMESO
Sector
Leveraged / InverseTechnology
52-Week High
$48.70$20.96
52-Week Low
$3.93$12.88
Market Cap
$2.16B
Enterprise Value
$2.17B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

GraniteShares 2x Long COIN Daily ETF

CONL (GraniteShares 2x Long COIN Daily ETF) trades at $4.38, up 11.45% in the past 24 hours but remains significantly below year-to-date levels with a 67% decline. Technical indicators show a bearish trend with moving averages signaling sell pressure, while oscillators remain neutral. The ETF tracks Coinbase stock with 2x daily leverage, exposing investors to amplified volatility from cryptocurrency market movements.

The outlook remains challenging due to the volatility decay inherent in daily-reset leveraged products. While recent cryptocurrency strength provides potential upside, the structural design of CONL creates significant long-term erosion risk. Investors should understand the product's mechanics before considering positions in this high-risk instrument.

Mesoblast Limited

MESO trades at $15.94, up 2.05% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Ryoncil net revenues of $36 million for Q2 2026 (GlobeNewsWire, July 29, 2026), showing commercial traction, yet fundamentals reveal a net loss of -$102.14 million in 2025 with a negative net margin. Valuation metrics include a P/S of 30.52 and P/B of 3.76, indicating high growth expectations.

Outlook hinges on Ryoncil's expansion and pipeline progress, but risks include sustained losses and regulatory hurdles. Analysts are cautiously optimistic with 45% buy ratings, yet the stock faces volatility from earnings misses and high cash burn.

Returns comparison

Trailing returns across standard periods

About GraniteShares 2x Long COIN Daily ETF

CONL is a leveraged ETF that seeks to provide two times (2x) the daily performance of Coinbase Global (COIN) stock. It is designed for investors seeking magnified short-term exposure to the price movements of Coinbase.

Read more on CONL

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

Read more on MESO